[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342206-105":59,"doc-detail-342206-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","redefining-therapeutic-approaches-in-colorectal-cancer-targeting-molecular-pathways-and-overcoming-resistance","Redefining Therapeutic Approaches in Colorectal Cancer - Targeting Molecular Pathways and Overcoming Resistance","","Colorectal cancer develops from interacting genetic and epigenetic alterations that reshape core tumor-driving pathways. This review surveys key molecular routes in CRC, focusing on chromosomal instability, microsatellite instability, and CpG island methylator phenotype, and explains how canonical mutations in APC, KRAS, NRAS, BRAF, and TP53 activate pathways including Wnt, EGFR, and PI3K/AKT. It also addresses resistance mechanisms that undermine targeted treatments. Molecular profiling is emphasized as a basis for selecting targeted and immunotherapeutic strategies, including novel combination regimens to improve outcomes and prognosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/redefining-therapeutic-approaches-in-colorectal-cancer-targeting-molecular-pathways-and-overcoming-resistance/342206/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/redefining-therapeutic-approaches-in-colorectal-cancer-targeting-molecular-pathways-and-overcoming-resistance/342206.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What molecular pathways are emphasized as drivers of colorectal cancer in this review?","Question",{"text":112,"@type":113},"The review highlights chromosomal instability (CIN), microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP) as major molecular pathways driving CRC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which gene mutations and signaling routes are discussed as contributing to tumorigenesis?",{"text":117,"@type":113},"Key mutations include APC, KRAS, NRAS, BRAF, and TP53. These activate pathways such as Wnt, EGFR, and PI3K/AKT, which contribute to cancer development and progression.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review connect molecular profiling to treatment selection?",{"text":121,"@type":113},"It explains that molecular profiling supports guiding the use of targeted therapies, including tyrosine kinase inhibitors and immune checkpoint inhibitors, to match tumor biology and improve response potential.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342206,1790160601,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Review  \nRedefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance  \nSimona Gabriela Duta-Ion 1,†, Ioana Ruxandra Juganaru 1, *,†, Iulian Andrei Hotinceanu 1, Andra Dan 1, Livia Malina Burtavel 1, Madalin Codrut Coman 1, Ina Ofelia Focsa 1, Andra Giorgiana Zaruha 1, Patricia Christina Codreanu 1, Laurentiu Camil Bohiltea 1,2 and Viorica Elena Radoi 1,2  \nCitation: Duta-Ion, S.G.; Juganaru, I.R.; Hotinceanu, I.A.; Dan, A.; Burtavel, L.M.; Coman, M.C.; Focsa, I.O.; Zaruha, A.G.; Codreanu, P.C.; Bohiltea, L.C.; et al. Redefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance. Int. J. Mol. Sci. 2024, 25, 12507 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms252312507  \nAcademic Editors: Jennifer Haynes and Carmine Stolfi  \nReceived: 24 October 2024  \nRevised: 12 November 2024  \nAccepted: 19 November 2024  \nPublished: 21 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Medical Genetics,“Carol Davila” University of Medicine and Pharmacy,  \n020021 Bucharest, Romania; [simona-gabriela.duta@rez.umfcd.ro](simona-gabriela.duta@rez.umfcd.ro) (S.G.D.-I.);  \n[iulian.hotinceanu@s.unibuc.ro](iulian.hotinceanu@s.unibuc.ro) (I.A.H.); [andra.dan@rez.umfcd.ro](andra.dan@rez.umfcd.ro) (A.D.);  \n[livia-malina.burtavel@rez.umfcd.ro](livia-malina.burtavel@rez.umfcd.ro) (L.M.B.); [madalin-codrut.coman@rez.umfcd.ro](madalin-codrut.coman@rez.umfcd.ro) (M.C.C.);  \n[ina.focsa@umfcd.ro](ina.focsa@umfcd.ro) (I.O.F.); [andra-giorgiana.zaruha@rez.umfcd.ro](andra-giorgiana.zaruha@rez.umfcd.ro) (A.G.Z.);  \n[patricia-christina.codreanu@rez.umfcd.ro](patricia-christina.codreanu@rez.umfcd.ro) (P.C.C.); [laurentiu.bohiltea@umfcd.ro](laurentiu.bohiltea@umfcd.ro) (L.C.B.);  \n[viorica.radoi@umfcd.ro](viorica.radoi@umfcd.ro) (V.E.R.)  \n2 “Alessandrescu-Rusescu” National Institute for Maternal and Child Health, 20382 Bucharest, Romania  \n* Correspondence: [ioana-ruxandra.calapod@rez.umfcd.ro](ioana-ruxandra.calapod@rez.umfcd.ro); Tel.: +40-746-091-505 † These authors contributed equally to this work.  \nAbstract: Colorectal cancer (CRC) arises through a combination of genetic and epigenetic alterations that affect key pathways involved in tumor growth and progression. This review examines the major molecular pathways driving CRC, including Chromosomal Instability (CIN), Microsatellite Instability (MSI), and the CpG Island Methylator Phenotype (CIMP). Key mutations in genes such as APC, KRAS, NRAS, BRAF, and TP53 activate signaling pathways like Wnt, EGFR, and PI3K/AKT, contributing to tumorigenesis and influencing responses to targeted therapies. Resistance mechanisms, including mutations that bypass drug action, remain challenging in CRC treatment. This review highlights the role of molecular profiling in guiding the use of targeted therapies such as tyrosine kinase inhibitors and immune checkpoint inhibitors. Novel combination treatments are also discussed as strategies to improve outcomes and overcome resistance. Understanding these molecular mechanisms is critical to advancing personalized treatment approaches in CRC and improving patient prognosis.  \nKeywords: colon cancer; targeted therapy; immunotherapy; BRAF mutations; MSI/dMMR; PI3K/ AKT/mTOR pathway; KRAS mutations; APC pathway  \n1. Introduction  \nColorectal cancer (CRC) represents the third most common cause of death in Europe, representing 11.6% of all cancer deaths and directly taking approximately 215,000–250,000 human lives in the European population yearly [1]. In Romania, colorectal cancer is a significant health concern, ran","cbCaik6NmKrR7wZF","https://ap.wps.com/l/cbCaik6NmKrR7wZF","pdf",1469135,"English","# Introduction\n# Molecular pathways in colorectal cancer\n## Chromosomal instability (CIN)\n## Microsatellite instability (MSI)\n## CpG island methylator phenotype (CIMP)\n# Targeted therapies and resistance mechanisms\n## Targeted therapy classes\n## Resistance to targeted treatments\n# Molecular profiling and personalized treatment","[{\"question\":\"What molecular pathways are emphasized as drivers of colorectal cancer in this review?\",\"answer\":\"The review highlights chromosomal instability (CIN), microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP) as major molecular pathways driving CRC.\"},{\"question\":\"Which gene mutations and signaling routes are discussed as contributing to tumorigenesis?\",\"answer\":\"Key mutations include APC, KRAS, NRAS, BRAF, and TP53. These activate pathways such as Wnt, EGFR, and PI3K/AKT, which contribute to cancer development and progression.\"},{\"question\":\"How does the review connect molecular profiling to treatment selection?\",\"answer\":\"It explains that molecular profiling supports guiding the use of targeted therapies, including tyrosine kinase inhibitors and immune checkpoint inhibitors, to match tumor biology and improve response potential.\"}]","Redefining Therapeutic Approaches in Colorectal Cancer - Targeting Molecular Pathways and Overcoming Resistance | PDF",1790045770,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32c895e7775ac369cecd0e30a8dd4c11.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/117a1b55d0fbb454762c64441bcac472.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e38e535769d60bca6a152745b575d5c.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc43f2768ed1b8bcbe475416956ba13c.webp",980,1385]